SillaJen, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: San Francisco CA United States (2003)
Status: Left NME R&D (2023)

Organization Overview

First Clinical Trial
2015
NCT02562755
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

SillaJen Biotherapeutics, Inc. | SillaJen, Inc.

Active Ingredients

Drugs in Phase 3 Trials (2)

Key: SillaJen, Inc. (0) Acquired (2)

pexastimogene devacirepvec (13 trials)

sorafenib (nexavar) (2 trials)

Drugs in Phase 2 Trials (1)

Key: SillaJen, Inc. (0) Acquired (1)

irinotecan (Camptosar) (1 trial)

Drugs in Phase 1 Trials (4)

bal0891 (1 trial)

carboplatin (paraplatin) (1 trial)

cemiplimab (libtayo) (1 trial)

paclitaxel (taxol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Renal Cell (Phase 1)

Vaccinia (Phase 3)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 14
  • # of Trial APIs: 7